SEARCH

SEARCH BY CITATION

References

  • 1
    Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 85964.
  • 2
    Djavan B, Zlotta A, Schulman C, Teillac P, Iversen P, Boccon GL, Bartsch G, Marberger M. Chemotherapeutic prevention studies of prostate cancer. J Urol 2004; 171: S10S13.
  • 3
    Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe? Cancer Res 2000; 60: 25715.
  • 4
    Lollini PL, Forni G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 2003; 24: 626.
  • 5
    Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3: 63041.
  • 6
    Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6: 20416.
  • 7
    Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 2004; 16: 14350.
  • 8
    Suckow MA, Wolter WR, Pollard M. Prevention of de novo prostate cancer by immunization with tumor-derived vaccines. Cancer Immunol Immunother 2005; 54: 5716.
  • 9
    Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 2005; 62: 21723.
  • 10
    Sobel RE, Sadar MD. Cell lines used in prostate cancer research: a compendium of old and new lines—part 2. J Urol 2005; 173: 36072.
  • 11
    Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 343943.
  • 12
    Foster BA, Kaplan PJ, Greenberg NM. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev 1998; 17: 31724.
  • 13
    Tani Y, Suttie A, Flake GP, Nyska A, Maronpot RR. Epithelial–stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Vet Pathol 2005; 42: 30614.
  • 14
    Granziero L, Krajewski S, Farness P, Yuan L, Courtney MK, Jackson MR, Peterson PA, Vitiello A. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur J Immunol 1999; 29: 112738.
  • 15
    Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C. Adoptive transfer of tumor-reactive transforming growth factor-β-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res 2005; 65: 17619.
  • 16
    Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60: 24448.
  • 17
    Hill RE, de Avila DM, Bertrand KP, Greenberg NM, Reeves JJ. Immunization against luteinizing hormone-releasing hormone fusion proteins does not decrease prostate cancer in the transgenic adenocarcinoma mouse prostate model. Exp Biol Med 2003; 228: 81822.
  • 18
    Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M, Monno A, Arcelloni C, Greenberg NM, Bellone M. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35: 6675.
  • 19
    Nikitina EY, Desai SA, Zhao X, Song W, Luo AZ, Gangula RD, Slawin KM, Spencer DM. Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res 2005; 65: 430919.
  • 20
    Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 2006; 55: 67283.
  • 21
    Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 15568.
  • 22
    Knowles BB, Koncar M, Pfizenmaier K, Solter D, Aden DP, Trinchieri G. Genetic control of the cytotoxic T cell response to SV40 tumor-associated specific antigen. J Immunol 1979; 122: 1798806.
  • 23
    De Giovanni C, Grilli S, Lollini PL, Nicoletti G, Prodi G, Nanni P. Inverse relationship between anti-SV40 TASA and anti-H-2 cytotoxic responses. J Cancer Res Clin Oncol 1983; 106: 11722.
  • 24
    Rovero S, Amici A, Carlo ED, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP,, et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165: 513342.
  • 25
    Nanni P, Rossi I, De Giovanni C, Landuzzi L, Nicoletti G, Stoppacciaro A, Parenza M, Colombo MP, Lollini PL. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res 1998; 58: 122530.
  • 26
    Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001; 194: 1195205.
  • 27
    De Giovanni C, Landuzzi L, Nicoletti G, Astolfi A, Croci S, Micaroni M, Nanni P, Lollini PL. Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. Int J Cancer 2004; 109: 2006.
  • 28
    De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, Musiani P, Cavallo F, et al. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. Cancer Res 2004; 64: 40019.
  • 29
    Ferrini S, Biassoni R, Moretta A, Bruzzone M, Nicolin A, Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterization of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer 1985; 36: 33743.
  • 30
    Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, Collins EJ, Frelinger JA, Joyce S, Tevethia SS. Quantitation of CD8+ T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J Virol 2000; 74: 692234.
  • 31
    Schell TD, Knowles BB, Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res 2000; 60: 300212.
  • 32
    Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res 2004; 64: 2270305.
  • 33
    Butel JS, Jarvis DL, Maxwell SA. SV40 T-antigen as a dual oncogene: structure and function of the plasma membrane-associated population. Ann N Y Acad Sci 1989; 567: 10421.
  • 34
    Kennedy RC, Shearer MH, Watts AM, Bright RK. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen. Cancer Res 2003; 63: 10405.
  • 35
    Dhanji S, Teh HS. IL-2-activated CD8+CD44high cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells. J Immunol 2003; 171: 344250.
  • 36
    Dhanji S, Tse K, Teh HS. The low affinity Fc receptor for IgG functions as an effective cytolytic receptor for self-specific CD8 T cells. J Immunol 2005; 174: 12538.
  • 37
    May T, Hauser H, Wirth D. Transcriptional control of SV40 T-antigen expression allows a complete reversion of immortalization. Nucleic Acids Res 2004; 32: 552938.
  • 38
    Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. J Urol 2005; 173: 177883.